RT Journal Article
SR Electronic
T1 Non-invasive prenatal testing of fetal aneuploidies using a new method based on digital droplet PCR and cell free fetal DNA
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.19.20248553
DO 10.1101/2020.12.19.20248553
A1 Wang Haidong
A1 Yang Zhijie
A1 Elena Picchiassi
A1 Federica Tarquini
A1 Giuliana Coata
A1 Wang You
A1 Wang Youxiang
A1 Chen Yu
A1 Gian Carlo Di Renzo
YR 2020
UL http://medrxiv.org/content/early/2020/12/22/2020.12.19.20248553.abstract
AB Background Current next generation sequencing (NGS) and microarray based Non-Invasive Prenatal Tests (NIPT), used for the detection of common fetal trisomies, are still expensive, time consuming and need to be performed in centralized laboratories. To improve NIPT in clinical routine practice as universal prenatal screening, we have developed a digital droplet PCR (ddPCR) based assay called iSAFE NIPT using cell free fetal DNA (cffDNA) for detection of fetal trisomies 13, 18 and 21 in a single reaction with advantage of high diagnostic accuracy and reduced cost.Materials and Methods We first used artificial DNA samples to evaluate analytical sensitivity and specificity of the iSAFE NIPT. Next, we analysed 269 plasma samples for the clinical validation of iSAFE NIPT. Fifty-eight of these, including five trisomies 21, two trisomies 18 and one trisomy 13 were utilised to establish the assay cut-off values based on ratios between chromosome counts. The remaining 211 plasma samples, including 10 trisomies 21, were analysed to evaluate iSAFE NIPT clinical performance.Results iSAFE NIPT achieved a 100% analytical sensitivity (95% CI 94.9-100% trisomy 21; 79.4-100% trisomy 18; 73.5-100% trisomy 13) and 100% specificity (95% CI 96.3-100% trisomy 21; 97.6-100% trisomy 18; 97.6-100% trisomy 13). It also achieved a 100% clinical sensitivity and specificity for trisomy 21 detection in the 211 clinical samples (95% CI for sensitivity is 69.1-100%, and 95% CI for specificity is 98.2-100%).Conclusions The iSAFE NIPT is a highly multiplexed ddPCR based assay for detection of fetal trisomies from maternal blood. Based on clinical validation, the iSAFE NIPT has high diagnostic sensitivity and specificity. It can be decentralized in routine clinical laboratories, is fast, easy to use and economical comparing to current NIPT.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the University of Perugia (Italy) Fondo Ricerca di Base 2018Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A total of 269 pregnant women at 11-27 weeks of gestation were enrolled. Seventy-eight samples were collected from the Obstetrics and Gynecology Outpatient Clinic of the University Hospital of Perugia (Italy) and 191 samples were collected by The Affiliated Huaian No.1 People's Hospital Nanjing Medical University (China). The study protocol was approved by the Medical Ethics Committee of the Region of Umbria, Italy (CEAS Umbria; approval no. 3352/18) and by the Affiliated Huaian No.1 People's Hospital Nanjing Medical University, China (Approval no. KY-P-2019-043-01). The experimental procedures adhered to the ethical standards for human experimentation of the 1975 Declaration of Helsinki (revised in 1983).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available.